Novel small-molecule inhibitors of the vascular endothelial growth factor receptor

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Sustained angiogenesis is one of the hallmarks of carcinogenesis. Vascular endothelial growth factor (VEGF) is a critical molecule mediating pro-angiogenic signals against which a number of therapeutic approaches have been designed. The 2 predominant approaches to inhibiting VEGF signaling are the use of monoclonal antibodies to block the receptor or ligand, and small-molecule receptor kinase inhibitors. There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review.

Original languageEnglish (US)
Pages (from-to)S74-S78
JournalClinical lung cancer
Issue numberSUPPL. 2
StatePublished - Feb 2007


  • AMG-706
  • Axitinib
  • Cediranib
  • Kinase inhibitors
  • Pazopanib
  • XL647

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Novel small-molecule inhibitors of the vascular endothelial growth factor receptor'. Together they form a unique fingerprint.

Cite this